Increase in Awareness Regarding Hospital Acquired Infection Favour the Growth of Ventilator-Associated Pneumonia Market; Asserts MRFR Unleashing Industry Forecast Up To 2027 :

Pune, India, December, 2017/MRFR Press Release/- Market Research Future published a Half-Cooked Research Report on “Global Ventilator-associated pneumonia (VAP) Market Research Report - Forecast to 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.

Merck & Co., Inc. (US), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) are some of the prominent players at the forefront of competition in the Global Ventilator-associated pneumonia (VAP) Market and are profiled in MRFR Analysis.

Global Ventilator-associated Pneumonia (VAP) Market - Overview

Patients in critical care require aid for respiration. Many of them suffer from disease like heart disease which require continuous monitoring by healthcare staff in intensive care unit. Ventilator- associated pneumonia is prevalent among patients admitted to ICUs. It is a significant cause of morbidity and mortality in ICU. This disease results from contaminated pathogen secretions in the lungs. Prolonged use of ventilators in ICU favour the growth of this market. Increase in hospital acquired infection is also another factor contributing for the growth of this market. Prevention of ventilator-associated pneumonia is important to protect the health of patients suffering from life threating diseases.

Global Ventilator-associated Pneumonia (VAP) Market - Competitive Analysis

June, 2016 - AstraZeneca had announced that the European Commission (EC) has granted marketing authorisation for Zavicefta, which a combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. AstraZeneca is a global, innovation-driven biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas which are respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology and infection and neuroscience. Company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. As per company reports, hospital-acquired pneumonia (HAP) denotes the development of lung infections after a patient has been hospitalised for a minimum of 48 hours. However, after 48 hours, the infection develops during the use of incubation and mechanical ventilation, the condition is then called ventilator associated pneumonia (VAP). VAP is generally a severe illness, with patients requiring treatment in the intensive care unit (ICU). The approval includes intravenous use of Zavicefta for the treatment of patients suffering from intra-abdominal infections (cIAI); Complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options. Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.

Jan, 2016 - Cepheid announced diagnostic collaboration with medimmune and combacte to facilitate clinical trials of new monoclonal antibodies to prevent serious infectious diseases. This Collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients. These tests will be used to help identify patients for MedImmune's MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use of biologics in preventing ventilator associated pneumonia (VAP) infections in intensive-care-unit (ICU) patients.

Philips Healthcare is one of the major market player in ventilation devices with its products named Respironic NM3, Respironic V680 and Respironic Trilogy 202.

Medtronic plc. is another major market player in this market with product like Puritan Bennet 980, Newport HT70 and Newport e360.

ResMed manufactures ventilation devices named Astral 150 and Astral 100.

Global Ventilator-associated pneumonia (VAP) Market   - Regional Analysis

Globally, Ventilator-associated pneumonia (VAP) market consists of four regions Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for Ventilator-associated pneumonia (VAP) whose growth is contributed to increase in prevalence of smoking leading to lung diseases, large number of patients suffering from chronic heart diseases and demand of mechanical ventilators. The market is growing continuously in Europe due to extensive demand of medical devices in hospitals, and increasing healthcare expenditure. Asia Pacific is expected to be the fastest growing market owing to increase in environmental pollution, high incidence of asthma & chronic obstructive pulmonary disease and large patient pool. Moreover, Awareness regarding prevention of hospital acquired infection, pneumonia and quality control measures taken by hospitals for control of nosocomial infection favour the growth of this market. Increasing ageing population and incidence of infectious disease too contribute for the growth of this market in Asia Pacific. On the other hand, the Middle East & Africa region are likely to have a limited but steady growth in the market.

Report Details @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com